|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.3795 EUR | +1.47% |
|
+3.69% | +27.35% |
| 07-01 | Nicox Submits NCX 470 New Drug Application In The United States | CI |
| 07-01 | Nicox files U.S. marketing approval application |  |
| Market Cap | 32.96M 37.54M 30.34M 28.27M 53.32M 3.57B 54.4M 365M 141M 1.75B 141M 138M 6.1B | P/E 2026 * |
-5.34x | P/E 2027 * | 37.4x |
|---|---|---|---|---|---|
| Enterprise Value | 32.96M 37.54M 30.34M 28.27M 53.32M 3.57B 54.4M 365M 141M 1.75B 141M 138M 6.1B | EV / Sales 2026 * |
11x | EV / Sales 2027 * | 3.3x |
| Free-Float |
99.65% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | +1.47% | ||
| 1 week | +3.69% | ||
| Current month | +0.53% | ||
| 1 month | +0.93% | ||
| 3 months | -6.99% | ||
| 6 months | +21.44% | ||
| Current year | +27.35% |
| 1 week | 0.36 |  | 0.41 |
| 1 month | 0.34 | | 0.42 |
| Current year | 0.29 | | 0.57 |
| 1 year | 0.22 | | 0.65 |
| 3 years | 0.14 | | 0.65 |
| 5 years | 0.14 | | 3.9 |
| 10 years | 0.14 | | 13.68 |
| Manager | Title | Age | Since |
|---|---|---|---|
Gavin Spencer
CEO | Chief Executive Officer | 55 | 28/02/2024 |
Sandrine Gestin
DFI | Director of Finance/CFO | 58 | 01/01/2015 |
Doug Hubatsch
CTO | Chief Tech/Sci/R&D Officer | - | 13/12/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Gavin Spencer
BRD | Director/Board Member | 55 | 08/04/2024 |
Damian Marron
CHM | Chairman | 64 | 16/07/2024 |
Marc Bozec
BRD | Director/Board Member | - | 16/07/2024 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 29/01/22 | Free | Chief Executive Officer | 15,000 | 0.0348% | ||
| 16/02/21 | Fiscal year | Chief Executive Officer | 10,000 | 0.0270% | ||
| 01/02/20 | Free | Chief Executive Officer | 10,000 | 0.0300% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.47% | +3.69% | +68.67% | -21.75% | 37.54M | |
| +2.24% | +2.31% | +55.78% | +12.26% | 310B | |
| +2.08% | +0.34% | +30.88% | -0.77% | 71.56B | |
| +1.80% | +8.12% | +45.87% | +112.95% | 9.13B | |
| +2.59% | +2.99% | +7.96% | -1.24% | 8.27B | |
| -0.12% | 0.00% | -6.28% | +7.05% | 4.38B | |
| -1.10% | +14.01% | +11.59% | +39.91% | 4.21B | |
| -0.57% | -3.04% | -33.17% | +21.86% | 3.39B | |
| +0.22% | +6.30% | +48.33% | +59.10% | 2.75B | |
| -1.31% | +6.66% | +16.30% | -21.65% | 2.24B | |
| Average | +0.75% | +6.30% | +24.59% | +20.77% | 41.56B | |
| Weighted average by Cap. | +2.15% | +6.70% | +48.24% | +12.39% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3M 3.42M 2.76M 2.57M 4.85M 325M 4.95M 33.21M 12.87M 159M 12.83M 12.55M 555M | 10M 11.39M 9.2M 8.58M 16.18M 1.08B 16.5M 111M 42.89M 532M 42.76M 41.84M 1.85B |
| Net income | -6M -6.83M -5.52M -5.15M -9.71M -650M -9.9M -66.43M -25.74M -319M -25.66M -25.1M -1.11B | 1M 1.14M 920K 858K 1.62M 108M 1.65M 11.07M 4.29M 53.15M 4.28M 4.18M 185M |
| Net Debt | - | - |
Employees
10
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/07/26 | €0.3795 | +1.47% | 113,619 |
| 01/07/26 | €0.3740 | -0.93% | 1,183,078 |
| 30/06/26 | €0.3775 | +0.94% | 173,088 |
| 29/06/26 | €0.3740 | +1.63% | 140,978 |
| 26/06/26 | €0.3680 | +0.55% | 84,940 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.3740EUR
Average target price
1.000EUR
Spread / Average Target
+167.38%
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ALCOX Stock
Select your edition
All financial news and data tailored to specific country editions
